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b-Catenin is a component of the E-cadherin-catenin cell adhesion
complex. It plays an important role in the Wnt/wg pathway, which
conveys critical signals for cell proliferation and transformation.
The b-catenin mutation is an important event in the progression of a
number of malignancies. In this study, we evaluated the immunohisto-
chemical (IHC) pattern of b-catenin in a spectrum of mesothelial
lesions. Sixty-five formalin-fixed, paraffin-embedded blocks from 54
serous effusions and 11 pleural biopsies were examined. These cases
consisted of 33 invasive mesotheliomas, 9 early mesotheliomas (with
negative radiologic finding), so-called mesotheliomas in situ, and 23
reactive mesothelial proliferations. A distinct membranous and/or
submembranous staining pattern was seen in 23 cases with normal
and reactive mesothelium. In contrast, reduced membranous and/or
submembranous antibody staining and markedly increased ectopic
cytoplasmic and nuclear staining was seen in 26 cases of 33 meso-
theliomas. Seven of 9 early mesotheliomas showed increased ectopic
cytoplasmic and/or nuclear stain. On the basis of our findings, iden-
tification of b-catenin staining pattern offers a useful marker in the
diagnosis of mesothelial lesions and may help identify neoplastic
change. Diagn. Cytopathol. 2005;33:320–324. ' 2005 Wiley-Liss, Inc.
Key Words: mesothelioma; mesothelial cells; b-catenin; pleural
fluid
Malignant mesothelioma is a rare and highly aggressive
neoplasm. Within the last 50 yr, enormous interest has
been generated by the rising incidence of this tumor, par-
ticularly after the recognition of asbestos as a main causa-
tive agent. Recently, as clinical management of mesothe-
lioma develops, innovative therapies such as the use of
targeted cytokines and gene therapy in early stage patients
require early diagnosis of malignant mesothelioma by
fluid cytology or small biopsy.1 However, a definitive
diagnosis of malignancy, enabling prompt therapeutic
decisions, is not always possible to obtain by conventional
fluid cytology and/or biopsy examination. Reactive meso-
thelial hyperplasia sometimes mimic malignancy, whereas
the morphologic alterations in malignancy are often quite
subtle and frequently pose diagnostic problems.2 There-
fore, there is a pressing need for markers that can reliably
facilitate distinguishing malignant mesothelioma from
benign proliferative mesothelium. b-Catenin is a multi-
functional protein. It mediates cell-to-cell adhesions
together with the transmembrane glycoprotein E-cadherin.
It is also an oncoprotein that can lead to carcinogenesis
when the adenomatous polyposis coli (APC)/b-catenin/
T-cell factor (Tcf) signal transduction pathway is dis-
rupted.3,4 In the normal cells membrane-binding b-catenin
is positive, but intracytoplasmic and nuclear b-catenin are
not detectable by immunohistochemical (IHC) stain
resulting in a distinct membranous staining. Recent stud-
ies have showed that accumulation of intracytoplasmic
and nuclear b-catenin is associated with malignant trans-
formation and unchecked cell proliferation of a wide
range of human neoplasms.5 b-Catenin mutation, to our
knowledge, have not been reported in mesothelial lesions.
We studied the IHC expression pattern of b-catenin in a spec-
trum of mesothelial lesions to determine its clinical utility.
Materials and Methods
Specimens
Sixty-five formalin-fixed, paraffin-embedded blocks from
54 serous effusions and 11 pleural biopsies were collected
during a 10-yr period from the University of Michigan
Hospitals and Northwestern University Hospital. These
cases consisted of 33 invasive Mesotheliomas (26 epithe-
lial type, 5 sarcomatous type, and 2 poorly differentiated
type), 9 early mesotheliomas (so-called mesothelioma in
situ), and 23 reactive mesothelial lesions including 4 cases
with florid papillary hyperplasia (with extensive papillary/
solid clusters). Early mesothelioma is defined according
to the criteria outlined by Whitaker et al.: (1) At the time
of work up, the patient had no gross tumor seen either at
open thoracotomy or pleuroscopy with the exception of
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minute sand grain-like spots or focal pleural thickening,
(2) No lesion was identified radiologically, and (3) The
diagnosis of malignant mesothelioma was established at
some stage in the development of the disease either on a
cytologic or histologic sample.6
IHC Analysis of b-Catenin
Five-micron sections of formalin-fixed, paraffin-embedded
tissue were mounted on Probe-On slides (Fisher Scientific,
Itasca, IL), deparaffinized in xylene, and then rehydrated
into distilled water through graded alcohols. Antigen
retrieval was enhanced by microwaving the slides in citrate
buffer (pH 6.0, Biogenex, San Ramon, CA) for 10 min.
Endogenous peroxidase activity was quenched by incuba-
tion with 3% hydrogen peroxide in methanol, and then
blocked with 1.5% normal horse serum for 1 hr. Sections
were incubated with a mouse monoclonal anti-b-catenin
antibody (C19220, Transduction Laboratories, Lexington,
KY) at a dilution of 1:500 overnight at 48C. Slides were
washed with PBS, and then incubated with a biotinylated
horse anti-mouse secondary antibody for 30 min at room
temperature. Antigen-antibody complexes were detected
with the avidin–biotin peroxidase method, using 3,30-di-
aminobenzidine as a chromogenic substrate (Vectastain
aneurysmal bone cyst (ABC) kit, Vector Laboratories, Bur-
lingame, CA). Immunostained sections were lightly coun-
ter-stained with hematoxylin, then examined by light
microscopy.
Scoring
Immunostaining was scored on a three tiered scale for
intensity (1þ, weak; 2þ, moderate; 3þ, strong) in the
mesothelial cell nuclei, cytoplasm, and cell membranes.
Scoring was done without knowledge of the diagnosis by
two pathologists separately. Reproducibility of scoring
was >85% both within and between scorers.
Results
Normal and Reactive Mesothelium
A distinct membranous and/or submembranous staining of
b-catenin was seen in 87% (20/23) of patients with nor-
mal and reactive mesothelioma (Fig. C-1, Table I). Only
a faint cytoplasmic staining was observed in 3 cases of
florid reactive mesothelium, but no nuclear expression of
b-catenin was present.
Invasive Mesothelioma
The fraction of cases showing membranous and/or sub-
membranous b-catenin staining was significantly lower in
21% (7/33) cases of invasive mesotheliomas. In contrast,
markedly increased ectopic cytoplasmic and/or nuclear
staining were seen in 79% (26/33) cases of invasive mes-
otheliomas (80% (21/26) epithelial type (Figs. C-2 and C-
3), 80% (4/5) sarcomatous type (Fig. C-4), and 50% (1/2)
poorly differentiated type). Interestingly, the intensity of
cytoplasmic and nuclear stain is significantly increased in
the deep invasive portion of the tumor (Fig. C-5).
Early Mesothelioma
The majority of early mesotheliomas 78% (7/9 cases)
showed increased ectopic cytoplasmic and/or nuclear
staining (Figs. C-6 and C-7). Membranous/submembra-
nous staining was observed only in the remaining two
cases.
Discussion
As innovative therapies bring the hope to the patients
with early stage mesothelioma, the demand for an early,
accurate diagnosis of mesothelioma became more press-
ing. However, the current approach for diagnosis of
malignant mesothelioma is still mainly dependent on clin-
ical and radiologic information in conjunction with patho-
logic tests. The common specimens used for pathologic
examination are transthoracic biopsy and effusion cyto-
logy. Although transthoracic biopsy is considered to have
a higher accuracy in diagnosing mesothelial lesions than
thoracentesis, the procedure has some disadvantages. The
morbidity is higher, the risk of spreading neoplastic cells
along the surgical site was reported, and it is difficult to
locate a small or superficial lesion. In comparison with
biopsy, cytological examination of effusion fluid is more
efficient and safe. This renders cytological examination of
effusion as the preferred choice for establishing the diag-
nosis, particularly in those cases of early mesothelioma.7
Many morphologic criteria have been proposed for the
diagnosis of malignant mesothelioma and separating it
from adenocarcinoma (ACA).8,9 However, the greatest
difficulty is in differential diagnosis of mesothelioma from
benign mesothelial hyperplasia.10 On the basis of the mor-
phologic criteria, the following three features are consid-
ered to have diagnostic value in tissue sections: presence
or absence of invasion, the extent of proliferation, and
cytological atypia. Because of the considerable morpho-
logic overlaps between well-differentiated mesothelioma
and mesothelial hyperplasia,11 none of these features is
diagnostic. Therefore, a biologic marker is needed for
facilitating the differential diagnosis.
Several recent studies revealed that b-catenin is a use-
ful marker of neoplastic cell transformation.12 b-catenin
has several important functions. One of the biologic func-
tions of b-catenin is cell-to-cell adhesion. In the adher-
ence junctions of epithelial cells, the cytoplasmic domain
of E-cadherin organizes a peripheral protein complex,
including a-catenin, b-catenin, and r-catenin, that is neces-
sary for adhesion to occur. The role of b-catenin in the
linkage between a-catenin and E-cadherin in this complex
is probably regulated by epidermal growth factor-medi-
ated tyrosine phosphorylation of the b-catenin. Reduced
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Figs. C-1–C-7. Fig. C-1. Reactive mesothelial cells in a cell block showing
positive membranous staining for b-catenin (100). Fig. C-2. Malignant
mesothelioma cells in a cell block showing positive membranous and
nuclear staining for b-catenin (100). Fig. C-3. Malignant mesothelioma
cells in a cell block showing positive cytoplasmic staining for b-catenin
(60). Fig. C-4. Cells of early mesothelioma in a cell block showing posi-
tive cytoplasmic staining for b-catenin (60). Fig. C-5. Cells of early meso-
thelioma in a cell block showing positive cytoplasmic staining for b-catenin
(40). Fig. C-6. Deep portion of malignant mesothelioma from a pleural
resection showing positive cytoplasmic and nuclear staining for b-catenin
(100). Fig. C-7. Sarcomatoid malignant mesothelioma from a pleural
resection showing positive cytoplasmic and nuclear staining for b-catenin
(40).
expression of b-catenin might lead to loss of adhesiveness
and increasing invasive and metastatic potential. It has
been reported that 100% of thyroid anaplastic carcinoma,
88% of head and neck squamous cell carcinomas, 70% of
esophageal carcinomas, and 30% of invasive ductal carci-
nomas of the breast show reduced membranous b-catenin
expression. Results of our study are similar: Twenty of
the 23 cases (87%) in reactive mesothelial lesions showed
membranous positivity. Only 7 of 33 (21%) malignant
mesotheliomas were positive for membranous b-catenin.
Two of 9 (22%) early mesotheliomas showed membra-
nous stain for b-catenin.
In contrast, cytoplasmic over expression of b-catenin
was identified in 24/33 (72%) malignant mesothelioma
cases, in 7/9 (78%) early mesothelioma, and only in 3/23
(13%) benign mesothelial hyperplasia cases. Nuclear posi-
tivity of b-catenin was revealed in 10/33 (30%) malignant
mesothelioma and 3/9 (34%) early mesotheliomas. No
nuclear stain of b-catenin was observed in normal or reac-
tive mesothelium. As many investigators reported,12 b-cat-
enin participates in the transduction of signals and acti-
vates transcription by forming complexes with DNA bind-
ing proteins in T-cell factor lymphoid enhancer factor
(TcF-lef) family.13 The free (cytoplasmic and nuclear) b-
catenin level is low in normal cells because APC protein,
together with glycogen synthesize kinase-3b (GSK-3b),
and other molecules such as axin, clear up unnecessary b-
catenin from the cytoplasm. Mutations that inactivate APC
increase cytoplasmic levels of free b-catenin and in the
same way, b-catenin gene mutations cause overexpression
of b-catenin in cytoplasm and nuclei as well. The b-cate-
nin accumulation in cytoplasm and nuclei has been shown
to be strongly associated with malignant transformation,
such as colon cancer, melanoma, hepatocellular carcinoma
(HCC), ovarian carcinoma, endometrial cancer, and pros-
tate cancer.14–16 Therefore, widespread b-catenin in the
cytoplasm and nucleus may be a potential marker of
malignant mesotheliomas. On the basis of our results, the
nuclear staining of b-catenin is more specific in distin-
guishing mesothelioma from benign mesothelial hyperpla-
sia. Therefore, nuclear staining of b-catenin has potential
application in the separation of cytologically bland malig-
nant mesothelioma from florid mesothelial hyperplasia.
Some studies found that the down-regulation of func-
tional adhesive b-catenin and over-expression of b-catenin
in cytoplasm and nucleus are associated with the degree
of dedifferentiation, and are directly related to the inva-
siveness of many human epithelial tumors.17 However,
our result does not reveal a strong association between
the degree of dedifferentiation and the degree of b-catenin
over-expression in cytoplasm and nucleus. The nuclear
and cytoplasmic positivities of b-catenin are 3/9(34%)
and 7/9(78%) in early mesothelioma (in situ); 10/33(30%)
and 24/33(72%) in invasive malignant mesothelioma. This
may be due to the fact that most malignant mesotheliomas
in our study are the well-differentiated epithelial types,
which do not show the same degree of down- regulation
as do other carcinomas.
In summary, this study revealed a distribution pattern
of b-catenin in mesothelial lesions, characterized by
decreasing of membranous and/or submembranous stain-
ing and increasing of nuclear/cytoplasmic staining with
the progression from benign reactive lesions to invasive
mesotheliomas. The patterns of b-catenin expression
within the lesions seem to parallel the spectrum of the
biologic change seen in these mesothelial proliferative
and neoplastic diseases. Identification of b-catenin stain-
ing pattern might offer a useful marker in the diagnosis
of mesothelial lesions and help identify neoplastic
changes. To our knowledge, this is the first study evaluat-
ing the expression of b-catenin in the spectrum of meso-
thelial proliferations and cytologic specimens. Additional
studies with a larger number of mesotheliomas, ideally
with both histologic and cytologic correlation, are needed
to further confirm the findings of this study.
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